Retatrutide appears to be a new treatment in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By stimulating these receptors, Retatrutide suppresses appetite, {promotesglucose regulation, and ultimately leads to significant weight loss. While further inv